TY - JOUR
T1 - Wake Forest University long-term follow-up of type 2 myocardial infarction
T2 - The Wake-Up T2MI Registry
AU - Jogu, Hanumantha R.
AU - Arora, Sameer
AU - Vaduganathan, Muthiah
AU - Qamar, Arman
AU - Pandey, Ambarish
AU - Chevli, Parag A.
AU - Pansuriya, Tusharkumar H.
AU - Ahmad, Muhammad I.
AU - Dutta, Abhishek
AU - Sunkara, Padageshwar R.
AU - Qureshi, Waqas
AU - Vasu, Sujethra
AU - Upadhya, Bharathi
AU - Bhatt, Deepak L.
AU - Januzzi, James L.
AU - Herrington, David
N1 - Funding Information:
We received valuable support from the Department of Hospital Medicine and Department Of Cardiology at Wake Forest Baptist Medical Center. We also want to acknowledge Diego Malaver for his role in the preliminary data analysis, and Dr Sreeja Sompalli, Dr Amit Vasireddy, and Dr Guru Anirudh Reddy Gopireddy for their work in data collection.
Funding Information:
Authors H.R.J., S.A., A.P., P.A.C., T.H.P., M.I.A., A.D., P.R.S., W.Q., S.V., and B.U. declare no potential conflict of interests. M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Bayer AG, and Baxter Healthcare, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH. A.Q. is supported by the NHLBI T32 postdoctoral training grant (T32HL007604) and the American Heart Association Strategically Focused Research Network in Vascular Disease grant (18SFRN3390085). D.L.B. discloses the following relationships—Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, Takeda. J.L.J. is supported in part by the Hutter Family Professorship, and has received grant support from Roche Diagnostics, Abbott Diagnostics, Singulex, Prevencio, Novartis and Cleveland Heart Labs, consulting income from Roche Diagnostics, Abbott, Prevencio and Critical Diagnostics and participates in clinical endpoint committees/data safety monitoring boards for Siemens Diagnostics, Novartis, Bayer, AbbVie and Amgen. D.H. receives grant support from the NIH and serves as a consultant to Amarin Corporation.
Publisher Copyright:
© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
PY - 2019/6
Y1 - 2019/6
N2 - Background: The Wake-Up T2MI Registry is a retrospective cohort study investigating patients with type 2 myocardial infarction (T2MI), acute myocardial injury, and chronic myocardial injury. We aim to explore risk stratification strategies and investigate clinical characteristics, management, and short- and long-term outcomes in this high-risk, understudied population. Methods: From 1 January 2009 to 31 December 2010, 2846 patients were identified with T2MI or myocardial injury defined as elevated cardiac troponin I with at least one value above the 99th percentile upper reference limit and coefficient of variation of 10% (>40 ng/L) and meeting our inclusion criteria. Data of at least two serial troponin values will be collected from the electronic health records to differentiate between acute and chronic myocardial injury. The Fourth Universal Definition will be used to classify patients as having (a) T2MI, (b) acute myocardial injury, or (c) chronic myocardial injury during the index hospitalization. Long-term mortality data will be collected through data linkage with the National Death Index and North Carolina State Vital Statistics. Results: We have collected data for a total of 2205 patients as of November 2018. The mean age of the population was 65.6 ± 16.9 years, 48% were men, and 64% were white. Common comorbidities included hypertension (71%), hyperlipidemia (35%), and diabetes mellitus (30%). At presentation, 40% were on aspirin, 38% on β-blockers, and 30% on statins. Conclusion: Improved characterization and profiling of this cohort may further efforts to identify evidence-based strategies to improve cardiovascular outcomes among patients with T2MI and myocardial injury.
AB - Background: The Wake-Up T2MI Registry is a retrospective cohort study investigating patients with type 2 myocardial infarction (T2MI), acute myocardial injury, and chronic myocardial injury. We aim to explore risk stratification strategies and investigate clinical characteristics, management, and short- and long-term outcomes in this high-risk, understudied population. Methods: From 1 January 2009 to 31 December 2010, 2846 patients were identified with T2MI or myocardial injury defined as elevated cardiac troponin I with at least one value above the 99th percentile upper reference limit and coefficient of variation of 10% (>40 ng/L) and meeting our inclusion criteria. Data of at least two serial troponin values will be collected from the electronic health records to differentiate between acute and chronic myocardial injury. The Fourth Universal Definition will be used to classify patients as having (a) T2MI, (b) acute myocardial injury, or (c) chronic myocardial injury during the index hospitalization. Long-term mortality data will be collected through data linkage with the National Death Index and North Carolina State Vital Statistics. Results: We have collected data for a total of 2205 patients as of November 2018. The mean age of the population was 65.6 ± 16.9 years, 48% were men, and 64% were white. Common comorbidities included hypertension (71%), hyperlipidemia (35%), and diabetes mellitus (30%). At presentation, 40% were on aspirin, 38% on β-blockers, and 30% on statins. Conclusion: Improved characterization and profiling of this cohort may further efforts to identify evidence-based strategies to improve cardiovascular outcomes among patients with T2MI and myocardial injury.
KW - acute myocardial injury
KW - chronic myocardial injury
KW - demand ischemia
KW - myonecrosis
KW - troponin
KW - type 2 myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85064560057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064560057&partnerID=8YFLogxK
U2 - 10.1002/clc.23182
DO - 10.1002/clc.23182
M3 - Article
C2 - 30941774
AN - SCOPUS:85064560057
SN - 0160-9289
VL - 42
SP - 592
EP - 604
JO - Clinical Cardiology
JF - Clinical Cardiology
IS - 6
ER -